Product Name: Thieno[3,2-d]pyrimidine, 2-(1H-indazol-4-yl)-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-(4-morpholinyl)-
Synonyms: Thieno[3,2-d]pyrimidine, 2-(1H-indazol-4-yl)-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-(4-morpholinyl)-;GDC-0941;GDC-0941 free base;2-(1H-Indazol-4-yl)-6-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-4-(4-morpholinyl)thieno[3,2-d]pyrimidine;GDC-0941 bismesylate;2-(1H-Indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine;4-(2-(1H-Indazol-4-yl)-6-((4-(Methylsulfonyl)piperazin-1-yl)Methyl)thieno[3,2-d];4-{6-[(4-Methanesulfonylpiperazin-1-yl)Methyl]-4-(Morpholin-4-yl)thieno[3,2-d]pyriMidin-2-yl}-1H-indazole
CAS: 957054-30-7
MF: C23H27N7O3S2
MW: 513.64
EINECS: 1312995-182-4
Product Categories: -;An inhibitor of class I PI3 kinase (PI3K).;Inhibitors;Akt;mTOR;PI3K
Uses GDC-0941 is a potent and selective oral inhibitor of the class I PI3K. GDC-0941 demonstrated broad spectrum of activity in breast, ovarian, lung, and prostate cancer models. Studies has also shown GDC -0941 may enhance anti-tumor activity of Docetaxel (D494420) in human breast cancer models.